Assessing non-inferiority of a new treatment in a three-arm trial in the presence of heteroscedasticity.

In this paper, we describe an adjusted method to facilitate non-inferiority tests in a three-arm design. While the methodology is readily available in the situation of homogeneous group variances, the adjusted method will also maintain the alpha-level in the presence of heteroscedasticity. We propose explicit criteria for an optimal allocation. Depending on the pattern of heterogeneity, remarkably unbalanced designs are power optimal. We will apply the method to a randomized clinical trial and a toxicological experiment.

[1]  Sue-Jane Wang,et al.  A Regulatory Perspective on Choice of Margin and Statistical Inference Issue in Non‐inferiority Trials , 2005, Biometrical journal. Biometrische Zeitschrift.

[2]  Iris Pigeot,et al.  Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo. , 2003, Statistics in medicine.

[3]  L A Hothorn,et al.  IDENTIFYING THE MAXIMUM SAFE DOSE: A MULTIPLE TESTING APPROACH , 2000, Journal of biopharmaceutical statistics.

[4]  Axel Munk,et al.  Therapeutic equivalence--clinical issues and statistical methodology in noninferiority trials. , 2005, Biometrical journal. Biometrische Zeitschrift.

[5]  Dieter Hauschke,et al.  Biostatistical Assessment of Mutagenicity Studies by Including the Positive Control , 2005, Biometrical journal. Biometrische Zeitschrift.

[6]  R. D'Agostino,et al.  Non‐inferiority trials: design concepts and issues – the encounters of academic consultants in statistics , 2002, Statistics in medicine.

[7]  J Singer,et al.  A simple procedure to compute the sample size needed to compare two independent groups when the population variances are unequal , 2001, Statistics in medicine.

[8]  J. Vallés,et al.  Low- vs high-dose almitrine combined with nitric oxide to prevent hypoxia during open-chest one-lung ventilation. , 2005, British journal of anaesthesia.

[9]  E. C. Fieller.  SOME PROBLEMS IN INTERVAL ESTIMATION , 1954 .

[10]  U. Kliesch,et al.  Comparison of single and multiple treatment regimens in the mouse bone marrow micronucleus assay for hydroquinone (HQ) and cyclophosphamide (CP). , 1990, Mutation research.

[11]  Iris Pigeot,et al.  Establishing Efficacy of a New Experimental Treatment in the ‘Gold Standard’ Design , 2005, Biometrical journal. Biometrische Zeitschrift.

[12]  R. Berger,et al.  Stepwise Confidence Intervals without Multiplicity Adjustment for Dose—Response and Toxicity Studies , 1999 .

[13]  B. L. Welch.  THE SIGNIFICANCE OF THE DIFFERENCE BETWEEN TWO MEANS WHEN THE POPULATION VARIANCES ARE UNEQUAL , 1938 .

[14]  T. Schwartz,et al.  A two‐stage sample size recalculation procedure for placebo‐ and active‐controlled non‐inferiority trials , 2006, Statistics in medicine.

[15]  S. Lange,et al.  Special Invited Papers Section: Therapeutic Equivalence – Clinical Issues and Statistical Methodology in Noninferiority Trials , 2005, Biometrical journal. Biometrische Zeitschrift.